Your browser doesn't support javascript.
loading
Beta-2-Glycoprotein-I Deficiency Could Precipitate an Antiphospholipid Syndrome-like Prothrombotic Situation in Patients With Coronavirus Disease 2019.
Serrano, Manuel; Espinosa, Gerard; Lalueza, Antonio; Bravo-Gallego, Luz Yadira; Diaz-Simón, Raquel; Garcinuño, Sara; Gil-Etayo, Javier; Moises, Jorge; Naranjo, Laura; Prieto-González, Sergio; Ruiz-Ortiz, Estibaliz; Sánchez, Beatriz; Moreno-Castaño, Ana Belen; Díaz-Pedroche, Carmen; Viñas-Gomis, Odette; Cervera, Ricard; Serrano, Antonio.
Afiliación
  • Serrano M; Hospital 12 de Octubre, Healthcare Research Institute and Hospital Clínico San Carlos, Madrid, Spain.
  • Espinosa G; Hospital Clínic, Institut d'Investigacions Biomèdiques August Pi i Sunyer, University of Barcelona, Barcelona, Catalonia, Spain.
  • Lalueza A; Hospital 12 de Octubre, Healthcare Research Institute I+12, Madrid, Spain.
  • Bravo-Gallego LY; Hospital Clínic, Institut d'Investigacions Biomèdiques August Pi i Sunyer, University of Barcelona, Barcelona, Catalonia, Spain.
  • Diaz-Simón R; Hospital 12 de Octubre, Healthcare Research Institute I+12, Madrid, Spain.
  • Garcinuño S; Hospital 12 de Octubre, Healthcare Research Institute I+12, Madrid, Spain.
  • Gil-Etayo J; Hospital 12 de Octubre, Healthcare Research Institute I+12, Madrid, Spain.
  • Moises J; Hospital Clínic, Institut d'Investigacions Biomèdiques August Pi i Sunyer, University of Barcelona, Barcelona, Catalonia, Spain.
  • Naranjo L; Hospital 12 de Octubre, Healthcare Research Institute I+12, Madrid, Spain.
  • Prieto-González S; Hospital Clínic, Institut d'Investigacions Biomèdiques August Pi i Sunyer, University of Barcelona, Barcelona, Catalonia, Spain.
  • Ruiz-Ortiz E; Hospital Clínic, Institut d'Investigacions Biomèdiques August Pi i Sunyer, University of Barcelona, Barcelona, Catalonia, Spain.
  • Sánchez B; Hospital Clínic, Institut d'Investigacions Biomèdiques August Pi i Sunyer, University of Barcelona, Barcelona, Catalonia, Spain.
  • Moreno-Castaño AB; Hospital Clínic, Institut d'Investigacions Biomèdiques August Pi i Sunyer, University of Barcelona, Barcelona, Catalonia, Spain.
  • Díaz-Pedroche C; Hospital 12 de Octubre, Healthcare Research Institute I+12, Madrid, Spain.
  • Viñas-Gomis O; Hospital Clínic, Institut d'Investigacions Biomèdiques August Pi i Sunyer, University of Barcelona, Barcelona, Catalonia, Spain.
  • Cervera R; Hospital Clínic, Institut d'Investigacions Biomèdiques August Pi i Sunyer, University of Barcelona, Barcelona, Catalonia, Spain.
  • Serrano A; Hospital 12 de Octubre, Healthcare Research Institute and Biomedical Research Centre Network for Epidemiology and Public Health, Madrid, Spain.
ACR Open Rheumatol ; 3(4): 267-276, 2021 Apr.
Article en En | MEDLINE | ID: mdl-33738987
OBJECTIVE: Patients with coronavirus disease 2019 (COVID-19) present coagulation abnormalities and thromboembolic events that resemble antiphospholipid syndrome (APS). This work has aimed to study the prevalence of APS-related antigens, antibodies, and immune complexes in patients with COVID-19 and their association with clinical events. METHODS: A prospective study was conducted on 474 adults with severe acute respiratory syndrome coronavirus 2 infection hospitalized in two Spanish university hospitals. Patients were evaluated for classic and extra-criteria antiphospholipid antibodies (aPLs), immunoglobulin G (IgG)/immunoglobulin M (IgM) anticardiolipin, IgG/IgM/immunoglobulin A (IgA) anti-ß2-glicoprotein-I (aß2GPI), IgG/IgM antiphosphatidylserine/prothrombin (aPS/PT), the immune complex of IgA aß2GPI (IgA-aß2GPI), bounded to ß2-glicoprotein-1 (ß2GPI) and ß2GPI levels soon after COVID-19 diagnosis and were followed-up until medical discharge or death. RESULTS: Prevalence of aPLs in patients with COVID-19 was as follows: classic aPLs, 5.8%; aPS/PT, 4.6%; IgA-aß2GPI, 15%; and any aPL, 21%. When patients were compared with individuals of a control group of a similar age, the only significant difference found was the higher prevalence of IgA-aß2GPI (odds ratio: 2.31; 95% confidence interval: 1.16-4.09). No significant differences were observed in survival, thrombosis, or ventilatory failure in aPL-positive versus aPL-negative patients. ß2GPI median levels were much lower in patients with COVID-19 (15.9 mg/l) than in blood donors (168.8 mg/l; P < 0.001). Only 3.5% of patients with COVID-19 had normal levels of ß2GPI (>85 mg/l). Low levels of ß2GPI were significantly associated with ventilatory failure (P = 0.026). CONCLUSION: ß2GPI levels were much lower in patients with COVID-19 than in healthy people. Low ß2GPI-levels were associated with ventilatory failure. No differences were observed in the COVID-19 evolution between aPL-positive and aPL-negative patients. Functional ß2GPI deficiency could trigger a clinical process similar to that seen in APS but in the absence of aPLs.

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Tipo de estudio: Observational_studies / Risk_factors_studies Idioma: En Revista: ACR Open Rheumatol Año: 2021 Tipo del documento: Article País de afiliación: España Pais de publicación: Estados Unidos

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Tipo de estudio: Observational_studies / Risk_factors_studies Idioma: En Revista: ACR Open Rheumatol Año: 2021 Tipo del documento: Article País de afiliación: España Pais de publicación: Estados Unidos